Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

NCT00005869 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: gemcitabine hydrochloride
DRUG: rubitecan

Sponsor

Astex Pharmaceuticals, Inc.